Safety and immunogenicity of a QazCovid-in® inactivated whole-virion vaccine against COVID-19 in healthy adults: A single-centre, randomised, single-blind, placebo-controlled phase 1 and an open-label phase 2 clinical trials with a 6 months follow-up in Kazakhstan

Safety and immunogenicity of a QazCovid-in® inactivated whole-virion vaccine against COVID-19 in healthy adults: A single-centre, randomised, single-blind, placebo-controlled phase 1 and an open-label phase 2 clinical trials with a 6 months follow-up in Kazakhstan

Background: A new inactivated whole-virion QazCovid-in® vaccine against COVID-19 was developed from SARS-CoV-2 isolated in Kazakhstan, inactivated by formaldehyde, and adjuvanted with aluminium hydroxide. Phase 1 and 2 clinical trials aimed at assessing the vaccine's safety, immunogenicity, and...

Full description

Bibliographic Details
Main Authors: Kunsulu Zakarya, Lespek Kutumbetov, Mukhit Orynbayev, Yergali Abduraimov, Kulyaisan Sultankulova, Markhabat Kassenov, Gulbanu Sarsenbayeva, Ilyas Kulmagambetov, Timur Davlyatshin, Maria Sergeeva, Marina Stukova, Berik Khairullin
Format: Article
Language:English
Published: Elsevier 2021-09-01
Series:EClinicalMedicine
Online Access:http://www.sciencedirect.com/science/article/pii/S2589537021003588

Internet

http://www.sciencedirect.com/science/article/pii/S2589537021003588

Similar Items